LAG3 and Parkinson disease: We reviewed advances in current trials to alleviate pathological α-Syn species in PD, including blocking pathways implicated in α-syn aggregation at the transcription level (e.g., ASO) or hindering propagation mechanisms that underlie the cell-to-cell transmission of α-Syn between neighboring neurons (e.g., LAG3 deletion).